Cargando…

Stat3 as a potential therapeutic target for rheumatoid arthritis

Rheumatoid arthritis (RA) is a multi-factorial disease characterized by chronic inflammation and destruction of multiple joints. To date, various biologic treatments for RA such as anti-tumor necrosis factor alpha antibodies have been developed; however, mechanisms underlying RA development remain u...

Descripción completa

Detalles Bibliográficos
Autores principales: Oike, Takatsugu, Sato, Yuiko, Kobayashi, Tami, Miyamoto, Kana, Nakamura, Satoshi, Kaneko, Yosuke, Kobayashi, Shu, Harato, Kengo, Saya, Hideyuki, Matsumoto, Morio, Nakamura, Masaya, Niki, Yasuo, Miyamoto, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591217/
https://www.ncbi.nlm.nih.gov/pubmed/28887478
http://dx.doi.org/10.1038/s41598-017-11233-w
_version_ 1783262666564829184
author Oike, Takatsugu
Sato, Yuiko
Kobayashi, Tami
Miyamoto, Kana
Nakamura, Satoshi
Kaneko, Yosuke
Kobayashi, Shu
Harato, Kengo
Saya, Hideyuki
Matsumoto, Morio
Nakamura, Masaya
Niki, Yasuo
Miyamoto, Takeshi
author_facet Oike, Takatsugu
Sato, Yuiko
Kobayashi, Tami
Miyamoto, Kana
Nakamura, Satoshi
Kaneko, Yosuke
Kobayashi, Shu
Harato, Kengo
Saya, Hideyuki
Matsumoto, Morio
Nakamura, Masaya
Niki, Yasuo
Miyamoto, Takeshi
author_sort Oike, Takatsugu
collection PubMed
description Rheumatoid arthritis (RA) is a multi-factorial disease characterized by chronic inflammation and destruction of multiple joints. To date, various biologic treatments for RA such as anti-tumor necrosis factor alpha antibodies have been developed; however, mechanisms underlying RA development remain unclear and targeted therapy for this condition has not been established. Here, we provide evidence that signal transducer and activator of transcription 3 (Stat3) promotes inflammation and joint erosion in a mouse model of arthritis. Stat3 global KO mice show early embryonic lethality; thus, we generated viable Stat3 conditional knockout adult mice and found that they were significantly resistant to collagen-induced arthritis (CIA), the most common RA model, compared with controls. We then used an in vitro culture system to screen ninety-six existing drugs to select Stat3 inhibitors and selected five candidate inhibitors. Among them, three significantly inhibited development of arthritis and joint erosion in CIA wild-type mice. These findings suggest that Stat3 inhibitors may serve as promising drugs for RA therapy.
format Online
Article
Text
id pubmed-5591217
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-55912172017-09-13 Stat3 as a potential therapeutic target for rheumatoid arthritis Oike, Takatsugu Sato, Yuiko Kobayashi, Tami Miyamoto, Kana Nakamura, Satoshi Kaneko, Yosuke Kobayashi, Shu Harato, Kengo Saya, Hideyuki Matsumoto, Morio Nakamura, Masaya Niki, Yasuo Miyamoto, Takeshi Sci Rep Article Rheumatoid arthritis (RA) is a multi-factorial disease characterized by chronic inflammation and destruction of multiple joints. To date, various biologic treatments for RA such as anti-tumor necrosis factor alpha antibodies have been developed; however, mechanisms underlying RA development remain unclear and targeted therapy for this condition has not been established. Here, we provide evidence that signal transducer and activator of transcription 3 (Stat3) promotes inflammation and joint erosion in a mouse model of arthritis. Stat3 global KO mice show early embryonic lethality; thus, we generated viable Stat3 conditional knockout adult mice and found that they were significantly resistant to collagen-induced arthritis (CIA), the most common RA model, compared with controls. We then used an in vitro culture system to screen ninety-six existing drugs to select Stat3 inhibitors and selected five candidate inhibitors. Among them, three significantly inhibited development of arthritis and joint erosion in CIA wild-type mice. These findings suggest that Stat3 inhibitors may serve as promising drugs for RA therapy. Nature Publishing Group UK 2017-09-08 /pmc/articles/PMC5591217/ /pubmed/28887478 http://dx.doi.org/10.1038/s41598-017-11233-w Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Oike, Takatsugu
Sato, Yuiko
Kobayashi, Tami
Miyamoto, Kana
Nakamura, Satoshi
Kaneko, Yosuke
Kobayashi, Shu
Harato, Kengo
Saya, Hideyuki
Matsumoto, Morio
Nakamura, Masaya
Niki, Yasuo
Miyamoto, Takeshi
Stat3 as a potential therapeutic target for rheumatoid arthritis
title Stat3 as a potential therapeutic target for rheumatoid arthritis
title_full Stat3 as a potential therapeutic target for rheumatoid arthritis
title_fullStr Stat3 as a potential therapeutic target for rheumatoid arthritis
title_full_unstemmed Stat3 as a potential therapeutic target for rheumatoid arthritis
title_short Stat3 as a potential therapeutic target for rheumatoid arthritis
title_sort stat3 as a potential therapeutic target for rheumatoid arthritis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591217/
https://www.ncbi.nlm.nih.gov/pubmed/28887478
http://dx.doi.org/10.1038/s41598-017-11233-w
work_keys_str_mv AT oiketakatsugu stat3asapotentialtherapeutictargetforrheumatoidarthritis
AT satoyuiko stat3asapotentialtherapeutictargetforrheumatoidarthritis
AT kobayashitami stat3asapotentialtherapeutictargetforrheumatoidarthritis
AT miyamotokana stat3asapotentialtherapeutictargetforrheumatoidarthritis
AT nakamurasatoshi stat3asapotentialtherapeutictargetforrheumatoidarthritis
AT kanekoyosuke stat3asapotentialtherapeutictargetforrheumatoidarthritis
AT kobayashishu stat3asapotentialtherapeutictargetforrheumatoidarthritis
AT haratokengo stat3asapotentialtherapeutictargetforrheumatoidarthritis
AT sayahideyuki stat3asapotentialtherapeutictargetforrheumatoidarthritis
AT matsumotomorio stat3asapotentialtherapeutictargetforrheumatoidarthritis
AT nakamuramasaya stat3asapotentialtherapeutictargetforrheumatoidarthritis
AT nikiyasuo stat3asapotentialtherapeutictargetforrheumatoidarthritis
AT miyamototakeshi stat3asapotentialtherapeutictargetforrheumatoidarthritis